Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has initiated a Phase I clinical trial of TC-2216, its product candidate for the treatment of depression and anxiety disorders. The trial is designed to evaluate the safety and tolerability of TC-2216 and to assess its pharmacokinetic profile. [click link for full article]
More...